Asthma May Protect You From Covid, Study Results

IN asthma doesn’t seem to be associated with worse development COVID-19 and yes, it could protect against this disease, at least in a certain group of patients with asthma, with the T2 phenotype, According to a study by pulmonologists Hospital Vall d’Hebron in Barcelona

The study, published Tuesday in ERJ Open Research, confirmed that only 3.2% of hospitalized patients with severe illness had asthma, which is a lower prevalence than in the general population, which is about 6%.

Asthma is one of the major respiratory diseases worldwide, and since SARS-CoV-2 is a respiratory pathogen, doctors at Vall d’Hebron wanted to quantify the risk that the current Covid-19 pandemic could pose to patients with asthma.

For this reason, a group of researchers from the Pneumology group of the Vall d’Hebron Research Institute (VHIR), led by Maria Jesus Cruz, VHIR Pneumology Team Leader, and Xavier Muñoz, the lead researcher of the same group, tried to find out if asthma is a risk factor for Covid-19 and found that asthma does not appear to be associated with worse development coronavirus

In a study of 71 asthma patients admitted to the Vall d’Hebron hospital for Covid pneumonia between March 1 and June 30, pulmonologists saw the importance of phenotypes because asthma may be a protective factor against SARS-CoV-2 infectionespecially in asthma patients with T2 phenotype.

The working hypothesis was based on the first studies published in China, Korea and New York on the relationship between SARS-CoV-2 and asthma patients in whom asthma has not been identified as a risk factor for Covid. -19 is serious.

Based on this information, the researchers estimated the prevalence of asthma in hospitalized patients with severe coronavirus pneumonia in the Barcelona area, where the prevalence of asthma is around 6%.

The study performed a cross-sectional analysis of all patients admitted to the Vall d’Hebron. with PCR-confirmed SARS-CoV-2 infection (2226 patients) and 71 patients with asthma, data were collected on the phenotype, severity and treatment of asthma.

The severity of Covid-19 was recorded based on oxygen and ventilation requirements and chest x-ray results.

Of the 71 patients, 42 had the Non-T2 phenotype, 20 were allergic (T2-Th2) and 9 were eosinophilic (T2-ILC2).

Patients with a phenotype other than T2 had a more severe form of Covid-19, but development with standard treatment was good in 67 (94%) patients, and four died.

Among patients receiving inhaled corticosteroid therapy for asthma no correlation was observed between the dose of inhaled corticosteroids and the severity of Covid-19.

Our results support the idea that asthma is not a risk factor. for the development of Covid-19, at least in hospitalized patients with more serious forms of infection, ”summed up Xavier Muñoz.

Then the researchers saw that 3.2% of hospitalized patients with severe illness suffered from asthma, which is lower than in the general population. was treated in this hospital.

“If we also take into account that 54 (76%) of 71 affected patients had comorbidities that have been shown to be directly related to SARS-CoV-2 involvement, the prevalence of asthmatics without other disorders suffering from severe illness is reduced. up to 0.8% ”, – said Maria Jesus Cruz.

Although some studies have shown that inhaled choricosteroids used to treat ASMa could protect against Covid, this study “found no relationship between the dose of inhaled corticosteroids and the severity of Covid-19, or a relationship between eosinophil levels and possible protection from the virus, nor was it found to exacerbate asthma like other coronaviruses.” Muñoz said.

“Although the present study The inherent limitations of the design suggest that asthma may be a protective factor. against SARS-CoV-2 infection, especially in patients with asthma with the T2 phenotype, and if replicated in studies with a large number of patients, they could open a new direction of research in the fight against Covid, ”concluded the pulmonologist.

Be the first to comment

Leave a Reply

Your email address will not be published.


*